Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma, Large B-Cell, Diffuse

Lymphoma

Lymphoma, Non-Hodgkin

Lymphoma, B-Cell

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

B-cell Lymphoma

Diffuse Large B-Cell Lymphoma

Lymphosarcoma

Antineoplastic Agents

All Drugs and Chemicals

Antirheumatic Agents

Molgramostim

Sargramostim

Rituximab

Antineoplastic Agents, Immunological

Immunologic Factors

Given 11 days before day 1 of cycle 1 for 10 days

GM-CSF

CHOP

Administered as part of standard treatment

Ephraim P Hochberg, MD

The primary goal of this study is to determine the effects (good and bad) of Granulocyte-macrophage colony stimulating factor (GM-CSF) in combination with Cytoxan, Adriamycin, Vincristine, Prednisone, Rituximab (CHOP-R) on diffuse Large B cell Non-Hodgkin's lymphoma (DLBCL). The standard of care for DLBCL is the combination of drugs known as CHOP-Rituximab (CHOP-R). The drugs that make up CHOP-R are the chemotherapy drugs cyclophosphamide, doxorubicin and vincristine, prednisone and rituximab. GM-CSF is a drug that stimulates the immune system by increasing the numbers of white blood cells. Previous research has shown that GM-CSF might help rituximab to be more effective in treating lymphoma.

* Study treatment is divided into 21-day time periods called cycles. Almost all participants will be treated as outpatients unless they have an existing medical problem that requires them to be treated as in inpatient.
* The drugs used in this study treatment are standard of care for this type of lymphoma and participants could receive these even if they are not taking part in the study.
* Participants will start receiving GM-CSF 11 days before Day 1 of Cycle 1 for 10 days. They will receive the first dose of GM-CSF at the clinic. At least 1 1/2 days after the last GM-CSF injection (Day 1), they will receive chemotherapy (CHOP-R). Eleven days before they start the next cycle (Days 11-20), they will again start to receive GM-CSF injections for 10 days.
* Participants will receive up to 6 cycles of study treatment if their disease is responding and they are tolerating the study treatment.
* Additional medications may be given to prevent lung infection, return of brain and nervous system disease and tumor lysis syndrome.
* Before beginning GM-CSF during each cycle of treatment blood will be drawn to monitor the participants health and to check for side effects.
* On Day 1 of each cycle a physical examination and blood tests will be performed. On Day 7 and Day 14 of each cycle, routine blood tests will also be done.
* After Cycle 2 and 4 CT scans of the neck, chest, abdomen and pelvis will be performed to check the status of the participants disease.
* After 6 cycles of study treatment, the participant will return to the clinic for an End of Treatment Visit. At this visit a physical exam, routine blood tests, and CT scan of neck, chest, abdomen and pelvis will be performed.
* The participant will be asked to return to the clinic every 3 months for the first year after study treatment and every 6 months up to 2 years after study treatment for the procedures outline in the End of Treatment Visit.

CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma

Phase II Trial of CHOP-Rituximab Augmented With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma

Beth Israel Deaconess Medical Center

Brigham and Women's Hospital

Dana-Farber Cancer Institute

Bayer

Massachusetts General Hospital

Director Clinical Lymphoma Research

Lymphoma, Mantle-Cell

Lymphoma, Follicular

Lymphoma, B-Cell, Marginal Zone

Mantle Cell Lymphoma

Follicular Lymphoma

Marginal Zone Lymphoma

Immunomodulating Agents

Veltuzumab

once weekly intravenous dosing for 4 weeks

veltuzumab

William Wegener, MD, PhD

This study is being done to assess the safety and tolerance of different doses of humanized hA20 in patients with NHL.

Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma

A Phase I Study of Immunotherapy With hA20 Administered Once Weekly for 4 Consecutive Weeks in Patients With CD20+ Non- Hodgkin's Lymphoma

Gilead Sciences

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma	NCT00455897	Lymphoma, Non-H... Lymphoma, B-Cel... Lymphoma, Diffu...	GM-CSF CHOP Rituximab	18 Years -	Massachusetts General Hospital
Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma	NCT00596804	Non-Hodgkin's L... Lymphoma, Diffu... Lymphoma, Diffu...	veltuzumab	18 Years -	Gilead Sciences
Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma	NCT00596804	Non-Hodgkin's L... Lymphoma, Diffu... Lymphoma, Diffu...	veltuzumab	18 Years -	Gilead Sciences
Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma	NCT00596804	Non-Hodgkin's L... Lymphoma, Diffu... Lymphoma, Diffu...	veltuzumab	18 Years -	Gilead Sciences
Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma	NCT00596804	Non-Hodgkin's L... Lymphoma, Diffu... Lymphoma, Diffu...	veltuzumab	18 Years -	Gilead Sciences

Spots Global Cancer Trial Database for lymphoma, diffuse